08.03.2013 - Bio-based polymers production capacity will triple to nearly 12 million tonnes in 2020, says study.
According to the largest ever market study published, bio-based drop-in PET and PE/PP polymers and the new polymers PLA and PHA show the fastest rates of market growth. However, Europe will stand only at the sidelines as the lion’s share of capital investment is expected to take place in Asia and South America, says the study conducted by the Cologne-based Nova Institute.
The global survey of 247 companies covered every kind of bio-based polymer and examines 114 companies in detail. Considerably higher production capacity was found compared to earlier studies. The Nova experts identified that there was a production capacity of 3.5 million tonnes in 2011 – a share of 1.5% of overall construction polymer production. According to estimates of the surveyed manufacturers, production capacity will raise to nearly 12 million tonnes by 2020. With an expected total polymer production of about 400 million tonnes in 2020, the bio-based share should increase from 1.5% in 2011 to 3% in 2020, meaning that bio-based production capacity will grow faster than overall production.
The most dynamic development is anticipated in drop-in biopolymers, which are chemically identical to their petrochemical counterparts but are at least partially derived from biomass. This group is spearheaded by partly bio-based PET (Bio-PET) of which production capacity will reach about 5 million tonnes by the year 2020, using bioethanol from sugar cane. The second in this group are bio-based polyolefins like PE and PP, also based on bioethanol. But “new in the market” bio-based polymers PLA and PHA are also expected to at least quadruple the capacity between 2011 and 2020. Most investment in new bio-based polymer capacities will take place in Asia and South America because of better access to feedstock and a favourable political framework. Europe’s share will decrease from 20% to 14% and North America’s share from 15% to 13%, whereas Asia’s will increase from 52% to 55% and South America’s from 13% to 18%. So world market shares are not expected to shift dramatically, which means that every region of the world will experience development in the field of bio-based polymer production.
27.04.2016 More revenue, more jobs, more financing, more R&D expenditure – all signs point towards sustainable growth in the German biotech sector. These are the results of the most recent company survey 2016, published by biotechnologie.de. The report was once again conducted alongside the biotech standards defined by the organisation for economic cooperation and development (OECD).
21.04.2016 An expert panel’s final report on the fatal drug trial earlier this year in France states that the death of one of the participants was most likely caused by the drug’s toxicity and not by any violation of the rules.
21.04.2016 For up to US$685m (€606m), Dutch ArgenX has outlicensed its human antibody programme ARGX-115 to AbbVie. The pre-clinical immuno-oncology candidate targets a protein believed to contribute to immunosuppressive effects of T-cells.
19.04.2016 British drug developer Heptares Therapeutics and mAb maker Kymab Ltd have partnered up in yet another immuno-oncology collaboration. The companies plan to discover antibody meds targeting a superfamily of receptors.
15.04.2016 Not every company is put off by the current stock market climate. Swiss biopharma company GeNeuro has gone public at Euronext Paris, raising €33m in the process. Others, meanwhile, have to find different ways to raise money.
13.04.2016 Despite political disturbances, 2015 was a good year for the biotech scene in Switzerland. Net sales increased by 5.1% to CHF5,133m and 400 additional people found jobs in the sector. As usual, the new numbers were presented at the annual Swiss Biotech Day – which set new records as well.
12.04.2016 German-Dutch life science investment specialist Forbion Capital Partners has raised more than €180m for its venture capital fund Forbion Capital Fund III. Once more the money will primarily go to European start-ups.
08.04.2016 Do you win by being innovative?, was the question asked at this year’s DIA Euromeeting in Hamburg. In a relaxed and cooperative atmosphere, regulators, physicians and patients had ample opportunity to interact with the healthcare industry.
07.04.2016 Pfizer and Allergan have called off their merger, cancelling plans to relocate the US pharma giant to Ireland to avoid US taxation. The US government has put a spoke in Pfizer’s wheels - an unfair move, Allergan says.